First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study by Rivera, Edgardo et al.
R114
Introduction
Neutropenic complications, defined as febrile neutropenia,
severe neutropenia, or dose delay or reduction due to neu-
tropenia, are the most common side effects of myelosup-
pressive chemotherapy [1,2]. The frequent occurrence of
neutropenic complications suggests that it is impossible to
predict accurately which patients will present with a neu-
tropenic complication. Febrile neutropenia, defined as an
absolute neutrophil count (ANC) of more than
1.0×109/liter with a temperature of more than 100.6°F, is
the most severe neutropenic complication and can cause
prolonged hospitalization. Neutropenic complications can
negatively affect the course of chemotherapy, leading to
dose delays or decreases to reduce a patient’s risk of devel-
oping febrile neutropenia. The ability to improve predictions
of which patients are at risk for neutropenic complications
ANC = absolute neutrophil count; CAF = chemotherapy with cyclophosphamide, doxorubicin, fluorouracil; MDACC = MD Anderson Cancer
Center.
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Abstract
Background: The nadir value of the absolute neutrophil count
(ANC) in the first cycle of chemotherapy is an effective
predictor of subsequent neutropenic events. This study was
designed to validate an earlier published study based on a
retrospective data analysis from a prospective randomized
clinical trial.
Methods: The original published model was applied to a trial
of 143 patients to cross-validate the model. We also tested
the specification of the model on our data by using a logistic
regression model with several variables, including first-cycle
nadir ANC, age, menopausal status, hormone-receptor
status, previous radiotherapy, and first-cycle decrease in
hemoglobin concentration. Patients received fluorouracil,
doxorubicin, and cyclophosphamide every 21 or 28 days for
six cycles without hematopoietic support from colony-
stimulating factor.
Results: In the cross-validation analysis, the original model
successfully classified patients by risk of neutropenic events
(C=0.78). When the model specification was tested, first-cycle
nadir ANC was the sole significant (P<0.0001) predictor of
neutropenic events and the model had a good predictive power
(C=0.78). The estimated relative risk of 4.8 did not differ from
the risk cited in the original model (P=0.91). A significantly
higher percentage of our patients with a low first-cycle nadir
ANC of 0.25×109/liter or less experienced febrile neutropenia
(30% versus 10%, P=0.04) and received at least 85% of the
planned dose intensity (55% versus 32%, P=0.05).
Conclusions: The original risk model used to predict neutropenic
events was validated by our study. This information can be used
to target high-risk patients for prophylactic treatment with
filgrastim (recombinant methionyl human granulocyte colony-
stimulating factor) in chemotherapy cycles 2 to 6.
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might help to reduce the morbidity due to febrile neutrope-
nia and increase the likelihood of delivering full chemother-
apy dose on time. In addition, hematopoietic growth factors
could be administered to patients who need them most,
permitting the more efficient use of medical resources.
Several publications have argued that the first chemother-
apy cycle nadir ANC is a good predictor of neutropenic
complications in patients with breast cancer [1,2]. These
papers were based on retrospective chart analyses and
therefore require further validation in additional chemother-
apy regimens and patient populations before the model
can be prospectively implemented.
Filgrastim (recombinant methionyl human granulocyte
colony-stimulating factor) has been shown to reduce the
depth of the nadir ANC, shorten the duration of neutro-
penia, and reduce the risk of febrile neutropenia [3],
thereby maintaining chemotherapy dose [4,5]. Many
patients with early-stage breast cancer do not receive the
full chemotherapy dose intensity recommended in conven-
tional adjuvant chemotherapy regimens [6–8]. Neutro-
penia is the primary reason for chemotherapy dose delays
and reductions [1,6,7].
Dose delay and dose reduction can result in care that is
less than optimal. Significant reductions in total dose and
dose intensity have an adverse effect on disease-free sur-
vival and overall survival [9,10]. Because most dose
delays and reductions occur after a neutropenic complica-
tion or febrile neutropenia, patients might experience an
infectious episode and might need to contend with the
burden and anxiety associated with a hospitalization and
the risk of prolonged complications in treatment. These
events impose potentially preventable burdens on the
patients. The use of hematopoietic growth factors as
primary prophylaxis is one way of decreasing the burden
of neutropenic complications. However, when growth
factors are not used as primary prophylaxis, neutropenic
complications serve as the indicator of the patient’s risk
for further neutropenic complications, resulting either in
growth-factor treatment as secondary prophylaxis or in
chemotherapy dose delays or reductions.
An alternative treatment strategy can be developed in
which patients have a reduced risk of neutropenic compli-
cations and a higher likelihood of receiving a full dose of
chemotherapy on time. First-cycle nadir ANC can be used
to identify patients at risk for neutropenic complications.
These patients could receive prophylactic hematopoietic
growth-factor support to decrease treatment-related mor-
bidity and to increase the likelihood of the administration
of full-dose chemotherapy on time.
Silber and colleagues [1] proposed a predictive model of
neutropenia, dose reduction, or dose delay based on
blood counts observed during the first cycle of chemother-
apy. The model estimates the patient’s risk of requiring
dose attenuation due to myelosuppression or, alterna-
tively, decreasing below acceptable ANC levels in subse-
quent chemotherapy cycles. The model demonstrates that
patients can be ranked by probability of presenting with
neutropenia in subsequent cycles with a high degree of
certainty and good degree of discrimination between
patients at high and low risk. This ranking permits the judi-
cious use of hematopoietic growth factors, such as filgra-
stim, to support patients who can benefit the most from
this treatment. Consequently, patients at high risk for
developing neutropenia will have a greater chance of
receiving full-dose chemotherapy on time and avoiding
febrile neutropenia.
The purpose of our study was the further validation of a
model [1,11] that used first-cycle nadir ANC count to
predict the risk of febrile neutropenia, dose delay, and
dose reduction in patients with breast cancer receiving
myelosuppressive chemotherapy. The validation had two
parts: a cross-validation of the original model with our data
and a test of the model specification to improve its predic-
tive power for our specific patient population and regimen.
Methods
Patients
The validation sample included 153 chemotherapy-naive
patients with stage I, II, IIIa, or IIIb breast cancer who had
been treated with adjuvant chemotherapy during
1986–92 as part of the MD Anderson Cancer Center
(MDACC) 86-12 trial. Patients aged more than 75 years,
those with inflammatory breast cancer, those with a previ-
ous history of contralateral breast cancer with higher
stage of disease, and those with second primary other
than basal cell carcinoma of skin or in situ carcinoma of
cervix were excluded from the original MDACC 86-12
study.
Of the 153 patients participating in the trial, 10 were
excluded from analysis. Four patients had no complete
blood cell count data recorded, three had incomplete
chemotherapy delivery information, and three had received
filgrastim. Results are reported for the remaining 143
patients. Therefore, as in the study by Silber and col-
leagues [1], this validation sample describes the natural
history of neutropenia.
Treatment
Primary surgical treatment consisted of a modified radical
mastectomy or segmental mastectomy. If indicated, the
patient was treated with preoperative or postoperative
local radiotherapy. All patients were treated with the FAC
(fluorouracil, doxorubicin, cyclophosphamide) regimen that
consisted of 50mg/m2 doxorubicin given as a continuous
infusion over 72 hours starting on day 1, 500mg/m2Breast Cancer Research    Vol 5 No 5 Rivera et al.
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cyclophosphamide intravenously on day 1, and 500mg/m2
fluorouracil intravenously on days 1 and 4. Treatment was
given every 3 or 4 weeks for a total of six cycles. Com-
plete blood counts with differential counts were usually
obtained on days 1, 8, and 15 of each cycle. Chemother-
apy was usually delayed if the ANC was less than
1.5×10 9/liter on the planned first day of the cycle. Dose
delays were usually for 1 week. The chemotherapy dose
was reduced if, on the previous cycle, the nadir ANC was
less than 0.5×109/liter or if the patient experienced an
episode of febrile neutropenia, defined as an ANC of less
than 1.0×109/liter with a temperature of more than
100.6°F. Dose reductions usually consisted of a 20%
reduction in dosage of all chemotherapy drugs.
Outcome definition
A neutropenia-related event was defined similarly to that in
the study by Silber and colleagues [1]: a nadir ANC of
0.5×10 9/liter or less, a neutropenia-related dose reduc-
tion of 15% or more of the planned dose of any agent, a
neutropenia-related dose delay of 7 days or more, or a
febrile–neutropenic episode. Delays and reductions were
related to neutropenia, and the reasons for the dose modi-
fications were documented. A response group for the risk
model consists of all patients who experienced at least
one neutropenia-related event after the first cycle of
chemotherapy. The ANC cutoff point to define an event
was 0.5×109/liter, rather than 0.25×109/liter used in the
Silber model to accommodate the physician practice style
associated with patients in the validation sample.
Statistical methods
The originally estimated Silber risk model was cross-vali-
dated with the MDACC sample. We used the same defini-
tions as in the original model for the predictor variables.
The distribution of these predictor variables was com-
pared across the original Silber and validation MDACC
study samples. The outcome variable in the validation
sample differs in that an ANC cutoff point of 0.5×109/liter
is used in the compound outcome definition. Given this
difference in ANC cutoff point and the difference in
chemotherapy regimens used in the two samples, the
absolute predicted probabilities of events resulting from
the cross-validation might not be interpretable, but their
relative magnitude (or ranking of patients by predicted
probability of an event) is valid. To assess the cross-valida-
tion results, we divided the patients into predicted positive
and predicted negative groups by using varying probability
cut points. This process is equivalent to ranking the
patients by their predicted event probability and dividing
the ranked list in all possible ways, declaring the higher-
ranked patients predicted positive and the lower-ranked
patients predicted negative.
The sensitivity and specificity of each possible resulting
classification are summarized in a receiver-operating-char-
acteristic curve plot. The C-statistic (area under the
receiver-operating-characteristic curve) [12], which sum-
marized the sensitivity and specificity across the entire
(0 to 1) range of probability cut points, is reported
together with the sensitivity and specificity rates for the
optimal classification table. This validation process does
not address the effect of concurrent radiotherapy because
none of the patients in the validation sample were treated
with this modality. As a result, the indicator variable for
concurrent radiotherapy present in the original model is
set to 0, effectively applying the model to patients with no
concurrent radiotherapy.
For the model-specification test, the same variables used
to predict neutropenic complications in the Silber model
were fitted with a logistic regression to our data and the
significance was reported. Furthermore, we explored other
potential predictors to examine whether new significant
risk factors would emerge. The discrimination and calibra-
tion of the model fitted to our data and original models
were compared by using the C-statistic and the
Hosmer–Lemeshow statistic [13]. The receiver-operating-
characteristic curves for the two models were plotted and
compared. The magnitudes of the risk factors’ effects
were compared across the validation and original models.
Regression coefficient differences were tested with an
asymptotic normal test and the estimated probability of
event curves derived from the original and validation
models were plotted for comparison. Finally, we assessed
the importance of first-cycle nadir ANC as a predictor of
subsequent episodes of febrile neutropenia and of
reduced dose intensity (not more than 85% of planned
dose intensity) by comparing the proportion of observed
events in patients grouped by first-cycle nadir ANC
ranges. Statistical analyses were performed by using SAS
8.00 for Windows (SAS Institute Inc, Cary, NC). All
reported P values are two-sided.
Results
Patients
Patient characteristics in the validation sample were
similar to those described in the Silber model [1], except
for the distribution of patients with positive nodes
(Table 1). In Silber’s patient sample, one-third of the
patients were treated with the less myelosuppressive CMF
(cyclophosphamide, methotrexate, fluorouracil) chemo-
therapy regimen, and the CAF (cyclophosphamide, doxo-
rubicin, fluorouracil) regimen consisted of 30mg/m2
compared with the 50mg/m2 CAF regimen used in our
validation sample. The rate of neutropenic events was
markedly higher among the validation patients than in
patients in the Silber study (84% versus 47%).
Outcome definition
The cross-validation of the Silber logistic regression model
applied to our data produced a C-statistic of 0.78. Thereceiver-operating-characteristic curve for this analysis
(Fig.1) can be compared with the receiver-operating-char-
acteristic curve from the original Silber model and an
MDACC data-fitted model. The predictions obtained from
the model for this independent set of patients confirm the
validity of the Silber model. As occurs typically, the predic-
tive power is not as high in a cross-validation as in the
original model development (C=0.83 in the Silber model),
but the cross-validation C-statistic is strong evidence for
the usefulness of the model. The cross-validation optimal
sensitivity and specificity rates (obtained for a cutoff prob-
ability of 0.45) were 66.6% and 73.3%, respectively.
The model fitted to the MDACC data (Table 2) confirms
the significance of the first-cycle nadir ANC effect
(P<0.0001). It was the only significant predictor of sub-
sequent neutropenic events among those available in the
validation sample, including age, menopausal status,
receptor status, previous radiotherapy, and first-cycle
hemoglobin decrease. The decrease in hemoglobin con-
centration from baseline to first-cycle nadir was only bor-
derline significant (P=0.0686). These results suggest that
the first-cycle nadir ANC is an excellent predictor of neu-
tropenic events in subsequent cycles. Model discrimina-
tion, as measured by the C-statistic (or the area under the
receiver-operating-characteristic curve), was similar in the
original Silber and validation studies (0.83 versus 0.78).
Figure 1 compares the receiver-operating-characteristic
curves for the Silber and validation models. As with the
Silber model, the validation model was well calibrated
throughout the entire range of probabilities, as assessed
by the nonsignificant Hosmer–Lemeshow statistic.
The MDACC model also confirms the magnitude of the
effect. The estimated odds ratio of 4.8 for a unit
(1.0×109/liter) decrease in first-cycle nadir ANC is not
significantly different from 4.4 in the Silber study. An
asymptotic  z-test for the comparison of the estimated
regression coefficients has a P value of 0.91. Estimates of
first-cycle hemoglobin decrease effects were almost iden-
tical across models.
Model-derived point estimates for the probability of subse-
quent neutropenic events as a function of first-cycle nadir
ANC and an average first-cycle decrease in hemoglobin
concentration are presented in Fig.2. The higher level of
the estimated probability curve for the MDACC sample
might be due to the higher myelotoxicity of the CAF
regimen used in the validation sample. The observed pro-
Available online http://breast-cancer-research.com/content/5/5/R114
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Table 1
Demographic and clinical characteristics of the MDACC study
sample compared with the sample used to develop the model
of Silber and colleagues [1]
MDACC Silber and
study patients colleagues’ patients
(1986–92) (1985–93)
Characteristic (n = 143) (n = 95)
Mean age (years) 46 (SD 10) 46 (SD N/A)
Menopausal status (%)
Pre- 55 60
Peri-, post, or surgical 45 40
Estrogen receptor status (%)
Positive 53 47
Negative 37 48
Unknown 10 4
Progesterone receptor status (%)
Positive 51 48
Negative 36 39
Unknown 13 13
Tumor size (cm) (%)
<2 36 41
2–5 58 52
>5 6 4
Unknown – 3
Number of nodes (%)
01 4 –
1–3 61 76
4–9 16 16
>9 9 5
Unknown – 3
All patient characteristics were insignificantly different between the two
samples, except for the number of positive nodes. N/A, not available.
Figure 1
Comparison of receiver-operating-characteristic curves for multiple
logistic regression models derived from the study by Silber and
colleagues [1] (n=95), the MDACC study (n=143), and the
cross-validation of the Silber model with the MDACC data. Dotted line,
Silber model; broken line, MDACC data; solid line, cross-validation.
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portions of patients who experienced febrile neutropenia
and received 85% or less of the planned dose intensity in
the MDACC study are presented in Figs 3 and 4 by first-
cycle nadir ANC. The association of the ANC at first-cycle
nadir with each of the outcomes is evident. A significantly
higher percentage of patients with a first-cycle nadir ANC
of 0.25×109/liter or less experienced febrile neutropenia
(30% versus 10%, P=0.04) and received 85% or less of
the planned dose intensity (55% versus 32%, P=0.05).
Discussion
Several retrospective analyses [1,2] using a variety of
chemotherapies have consistently resulted in first-cycle
nadir ANC as a primary predictor of neutropenia-related
events in patients with breast cancer. Here we confirm the
results obtained in the previous analyses by Silber and
colleagues [1], which is important because the data used
in this study come from a prospective clinical trial,
Table 2
Multiple logistic regression models for the validation and Silber and colleagues [1] studies
MDACC study Silber model
Variable Odds ratio 95% CI P Odds ratio 95% CI P
Radiotherapy + chemotherapy indicatora – 9.5 2.5–36.6 0.0011
Cycle 1 nadir ANC (×109/liter) 4.8 2.3–9.9 <0.0001 4.4 2.1–9.2 <0.0001
Cycle 1 hemoglobin decrease (g/dl) 1.8 1.0–3.3 0.0686 1.8 1.2–2.8 0.0074
n 143 95
Model χ2 21.2 (2 df) 30.3 (3 df)
Log-likelihood P <0.0001 <0.0001
C-statistic 0.78 0.83
Hosmer–Lemeshow lack-of-fit P 0.1268 0.6140
CI, confidence interval; df, degrees of freedom.
aNot applicable to MDACC study because patients were not treated with concurrent radiotherapy.
Figure 2
Probability of neutropenic-related event based on cycle 1 nadir ANC
and average hemoglobin decrease at each sample. Point estimates
derived from the Silber and MDACC multiple logistic regression
models. Solid line, validation model; dotted line, Silber model.
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Figure 3
Rates of febrile neutropenia by first-cycle nadir ANC in the MDACC
sample. Numbers of patients are shown above bars.
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awhereas the other data sets were collected from patient
charts in an uncontrolled environment. The data in this
study represent a homogenous population receiving stan-
dardized chemotherapy, and the collection procedures
ensure high-quality data. The cross-validation analysis
showed that the original predictive model successfully
classified patients by their risk of neutropenic event. The
model fitted to the validation data results in the same
specification and similar variable coefficient magnitudes to
those in the original model.
Our model differs somewhat from the Silber model. First,
the impact of the change in hemoglobin concentration is
significant in the Silber model and not significant in this
data set, although the magnitude of the effect is similar in
both models. We do not believe that hemoglobin concen-
trations have a direct impact on neutropenic complica-
tions; however, low hemoglobin concentrations probably
provide further indication of bone marrow depletion. It is
possible that the impact of change in hemoglobin concen-
tration in the models will vary by chemotherapy regimen.
On the basis of the cumulated published evidence, the
model seems to be robust. The model was tested in
several chemotherapy regimens and in various clinical
environments. It seems that the model’s specification and
the magnitude of the coefficient’s effect is consistent
across chemotherapy regimens. The inclination is to con-
sider the implementation of this model prospectively.
Before such a step is undertaken, some issues need to be
discussed to improve our understanding of the model’s
limitation and its usefulness.
The major challenge to the model’s prospective implemen-
tation is the uncertainty that a greater dose intensity would
result in clinical benefit, such as survival. Although it is not
within the scope of this study to answer this important
question, it should be emphasized that the model provides
some other distinctive and practical benefits. Successful
application of the model will clearly define the patient
group that should not receive growth-factor support and
who can receive the full dose on time without a risk of com-
plications. The ability to define the population that does not
require growth factors on the basis of a quantitative clinical
indicator has an immediate benefit to the patients and the
health care system: it diverts resources from patients who
will not benefit to those who will. The second benefit is the
potential to reduce the morbidity due to febrile neutropenia
from the high-risk group by providing these patients with
growth-factor support before any clinical complications
occur. The third benefit is learning the relationship between
high dose intensity and survival on the basis of planned
dose and not actual delivered dose. Implementation of a
risk model can provide better data by making the planned
dose closer to the delivered dose, and the impact of dose
can be measured more accurately.
Additional objections to the model relate to the definition
of a neutropenic complication, in particular dose delays
and dose reductions. Dose delays and dose reductions
are events that occur as a result of a clinical decision and
not a measured biological variable such as neutropenia
based on ANC. It could be argued that these decisions
are not necessarily objective, reflecting the practice
pattern of individual physicians, and cannot be part of the
definition of a neutropenic complication. In this context it is
important to remember that the purpose of the model is to
identify patients at risk. A physician who delays or reduces
the dose of chemotherapy has decided that the patient is
at risk. Moreover, once it is decided to reduce or delay the
dose, there is no way of knowing the rate of neutropenia
or febrile neutropenia if the full dose of chemotherapy had
been delivered. Therefore, including these events in the
definition of a neutropenic complication seems justified,
especially if the goal is to minimize harm to the patients.
Admittedly, this methodology might result in an overesti-
mation of the number of patients at risk.
Although the model seems to be robust and potentially
useful, it does not answer the following two major ques-
tions. If patients were stratified by their risk for neutropenic
complications and provided with growth-factor support,
would the dose intensity delivered increase and by how
much? Would the rate of neutropenic complications
Available online http://breast-cancer-research.com/content/5/5/R114
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Figure 4
Rates of patients with a dose intensity not more than 85% of planned
by first-cycle nadir ANC in the MDACC sample. Numbers of patients
are shown above bars.
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ered? To answer these questions decisively, the model
needs to be implemented prospectively.
Conclusions
The first step toward the prospective implementation of
the model has been performed and is reported by Rivera
and colleagues [14]. Additional prospective studies on dif-
ferent regimens and different cancer types would be
required to establish the utility and feasibility of this model.
Such an effort carries with it the promise that clinical
criteria would be used to deliver appropriate care to
patients with cancer and would maximize the potential
benefit from chemotherapy while possibly minimizing the
burden on patients and their caregivers and families.
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